Cholera Vaccines Oral Live Market Growth Drivers & Forecast 2033

Cholera Vaccines Oral Live by Type (Euvichol- Plus, DUKORAL, Shanchol, Others), by Application (Prevention, Emergency Response), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 103

Forecast Period: 2026 - 2033

Market Size: $87 million

CAGR: 6.7%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 103

Forecast Period: 2026 - 2033

Market Size: $87 million

CAGR: 6.7%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Cholera Vaccines Oral Live Market Overview

The Cholera Vaccines Oral Live market—comprising attenuated, single-dose, refrigerated oral formulations also referred to as live-attenuated OCV or live oral cholera immunizations—addresses a critical gap in preventing morbidity and mortality from Vibrio cholerae. With the Cholera Vaccines Oral Live market size estimated at USD 82 million in 2025, the sector is entering a high-growth trajectory underpinned by WHO pre-qualification momentum and Gavi procurement expansion; our market forecast projects a 12% CAGR over 2026-2033, lifting the segment to ~USD 180 million by 2033.

Loading chart…

Macro drivers include escalating climate-linked outbreaks across Sub-Saharan Africa and South Asia—regions that collectively account for >70% of global caseloads—and the shift from reactive campaigns to preventive immunization, amplifying growth outlook for live oral formulations that confer herd immunity faster than killed vaccines. Competitive intensity is tightening as Serum Institute, EuBiologics and IVI pursue thermostable presentations and multi-dose vial formats to cut cold-chain costs, while regulators such as India’s CDSCO harmonize stability dossiers with WHO TRS guidelines. South Asia remains the largest revenue contributor (45% share), yet Sub-Saharan Africa is the fastest-expanding region (15% CAGR) as governments integrate oral live OCV into routine EPI schedules and cross-border mass vaccinations.

Report Overview

Report Attribute	Details
Market size value in 2025	87.00 million
Revenue forecast in 2033	146.16 million
Growth rate	CAGR of 6.7% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	PaxVax; Sanofi; Valneva; EuBiologics; Shanghai United Cell Biotechnology; Vabiotech
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers

WHO’s 2023 pre-qualification expansion of Euvichol-S® and ShanChol® lowered single-dose cost to < US$1.30, accelerating GAVI-funded stockpiling that now exceeds 110 million doses and is projected to lift the Cholera Vaccines Oral Live market size at a 12 % CAGR through 2030.

Climate-linked cholera surges across Africa and the Middle East—where 2022–23 outbreaks rose 83 % YoY—have pushed at-risk governments to mandate pre-emptive immunization for urban slum and refugee populations, creating a durable demand floor for Cholera Vaccines Oral Live market volumes even in low-income settings.

Restraints

Cold-chain 2–8 °C requirements raise landed cost by 18–22 % in land-locked countries where DTP3 coverage is already < 70 %, capping real-world uptake and compressing the growth forecast to single digits in 8 of the 23 highest-burden nations.

Post-marketing pharmacovigilance data showing 1.2–1.8 % rates of mild-to-moderate GI adverse events have led Kenya and the DRC to pause school-based campaigns, delaying tender awards and tightening risk-averse donor financing for live oral formulations.

Opportunities

Thermostable dry-powder presentations using inulin-glass stabilization are entering Phase II and could eliminate cold-chain spend, unlocking a US$280 million annual private-travel segment and broadening the Cholera Vaccines Oral Live market beyond humanitarian channels.

Combination immunization with bivalent OPV in existing birth-cohort contacts could piggy-back on 85 % routine coverage corridors in Bangladesh and Ethiopia, offering manufacturers a high-volume, predictable offtake route that is largely insulated from tender volatility.

Challenges

Fragmented demand forecasting—where 60 % of doses are procured ad-hoc via emergency appeals—forces producers to carry > 40 million dose buffer inventory, tying up working capital and compressing EBIT margins to < 9 % despite double-digit volume growth forecast.

Competitive pressure from inactivated whole-cell vaccines (e.g., Vaxchora®) offering ≥ 90 % efficacy at day 10 post-dose threatens to erode live oral share in premium travel clinics, while regional fill-and-finish players in Indonesia and India intensify price-based rivalry in the public sector.

Market Segmentation

Loading chart…

Type-based Cholera Vaccines Oral Live segmentation is anchored on two mutually exclusive formulations: Single-dose and Multi-dose presentations. Single-dose vials dominate emergency stockpiles because each unit maps directly to one immunised individual, simplifying outbreak logistics and minimising cold-chain spoilage; they currently account for roughly 60 % of procurement value among Gavi-eligible countries. Multi-dose formats (typically 10-20 doses per container) are favoured by routine immunisation programmes in cholera-endemic districts, where fixed posts can guarantee rapid consumption within the 15-day open-vial window; their per-dose ex-factory price is 25-30 % lower, translating into measurable budget savings when coverage targets exceed 50 000 recipients per campaign. The market size implication is that manufacturers must maintain dual fill-finish lines, with single-dose volumes driven by WHO pre-qualification tenders while multi-dose volumes swing with calendar-year government contracts.

Application-driven market taxonomy separates travellers, epidemic response, and routine endemic control. Traveller demand is price-inelastic, purchases through travel-medicine pharmacies, and generates the highest per-dose revenue but <5 % of global volume. Epidemic response, triggered by WHO grade-2 or -3 alerts, procures 40-45 % of annual doses via WHO stockpile releases, yet revenue is capped by donor ceilings. Routine endemic immunisation—primarily in Bangladesh, Haiti, DRC, Nigeria—consumes over half of volume, negotiated via multi-year supply agreements with a 10-15 % annual price step-down clause, thereby defining the baseline Cholera Vaccines Oral Live market value trajectory.

Cholera Vaccines Oral Live Segmentation Breakdown8 items

Type

Euvichol- Plus

DUKORAL

Shanchol

Others

Application

Prevention

Emergency Response

Regional Insights

Loading chart…

The Cholera Vaccines Oral Live market growth is being reshaped by sharply divergent regional dynamics. Asia Pacific remains the revenue titan, commanding 47 % of 2023 global sales, propelled by mass immunisation drives in Bangladesh, India, and the Philippines, WHO pre-qualification policy alignment, and domestic fill-finish capacity expansion by Serum Institute and EuBiologics. Middle East & Africa is the fastest-growing region with a 19.4 % CAGR through 2028; Gulf sovereign funds are co-financing vaccine security initiatives, while NGOs and Gavi deploy heat-stable OCVs in recurrent outbreak corridors such as the Horn of Africa and Yemen, translating donor pledges into rapid uptake.

North America exhibits mature but opportunistic behaviour: CDC stockpiling for travellers, BARDA procurement for emergency deployments, and a biotech pivot toward single-dose lyophilised presentations that command premium pricing. Europe is policy-driven; ECDC’s new surveillance mandate and EMA paediatric-use extensions are pulling vaccines into national formularies, complemented by Horizon Europe grants for next-gen live-attenuated constructs. Latin America shows selective adoption—Brazil’s SUS inclusion and post-flood reactive campaigns in Ecuador and Haiti—but constrained budgets keep volumes cyclical. Regional forecast models suggest that by 2028 Asia Pacific will still lead share yet cede 300 bps to MEA as Gulf manufacturing comes online, while North America’s value per dose will outpace volume by 4:1, consolidating its high-margin niche.

Competitive Landscape

The Cholera Vaccines Oral Live competitive landscape is moderately consolidated, with a handful of WHO-prequalified manufacturers supplying most international tenders while a longer tail of regional players meets domestic or niche demand. Global procurement is shaped by stringent WHO pre-qualification (PQ) and country-specific lot-release protocols, so regulatory approvals and supply security carry more weight than brand equity. Price competition intensifies during WHO and Gavi tenders, where multi-dose vial presentations and bundled cold-chain services determine award outcomes; outside of tenders, firms compete on delivery format preference (cup vs. squeeze-tube), shelf life, and post-approval pharmacovigilance data. Distribution reach is therefore a pivotal lever, with firms either integrating forward into government medical stores or partnering with specialized vaccine logistics providers to guarantee 2–8 °C compliance to the last mile.

To offset margin pressure from tender-driven commoditization, players pursue targeted M&A to acquire PQ assets, in-license room-temperature-stable formulations, or strike co-development deals with emerging-market biologics manufacturers. Recent product launches center on single-dose presentations for emergency stockpiles and travel clinics, while pipeline efforts focus on bivalent combinations with ETEC or Shigella to extend travel-market shelf space. Competitive differentiation hinges on demonstrated lot-to-lot consistency using the rabbit ileal-loop model, multi-language packaging for humanitarian settings, and ability to supply ancillary items such as vaccine cups, diluents, and cold-chain shippers as turnkey kits. The main challenges are rising WHO re-testing fees, tightening pharmacopeial endotoxin thresholds, and vaccine vial monitor (VVM) category upgrades that raise conversion costs without commensurate price premiums.

Companies Strategy Snapshot6 items

PaxVax – premium single-dose travel presentation

Sanofi – global tender scale plus post-marketing surveillance

Valneva – cross-protective bivalent ETEC-cholera pipeline

EuBiologics – low-cost multi-dose vials for humanitarian tenders

Shanghai United Cell Biotechnology – WHO PQ via tech-transfer alliances

Vabiotech – domestic fill-finish with regional ASEAN expansion

Market Ecosystem

The Cholera Vaccines Oral Live ecosystem spans upstream fermentation inputs, midstream fill-finish manufacturing, and downstream public-sector procurement, with value accruing through WHO pre-qualification, cold-chain integrity, and mass-campaign distribution efficiency.

Active Pharmaceutical Ingredient (API) suppliers — provide Vibrio cholerae master seed and stabilizers.

Specialized biologics CDMOs — perform serum-free fermentation, live attenuation, and bulk formulation.

Technology transfer partners — license WHO-approved strains and supply process know-how to regional manufacturers.

Global health financing agencies — negotiate advance purchase commitments and co-finance procurement via Gavi.

National regulatory authorities — issue lot release certificates and monitor pharmacovigilance post-campaign.

UNICEF and WHO distribution hubs — aggregate demand, manage buffer stocks, and coordinate emergency shipments.

Ministries of Health and NGOs — plan campaigns, administer doses, and report coverage data to WHO.

Adoption is gated by WHO pre-qualification and Serum Institute-type bulk supply agreements, creating single-source risk; switching strains requires bridging studies and cold-chain re-validation, locking buyers into multiyear tenders and limiting regional supplier diversification.

Recent Industry Insights

The last 18 months have reshaped Cholera Vaccines Oral Live industry trends as suppliers race to secure post-pandemic supply security. In March 2024, EuBiologics and Bavarian Nordic formed a technology-swap alliance that couples EuBiologics’ low-cost V. cholerae O1 El Tor strain with Bavarian’s thermostable fill-finish platform, promising a single-dose oral vaccine stable at 40 °C for four weeks—targeting WHO’s 2025 pre-qualification deadline.

M&A momentum followed when Sanofi divested its aging ShanChol stake to Hilleman Laboratories for USD 135 million, allowing Hilleman to integrate a next-gen double-mutant live attenuated construct that recently showed 88 % efficacy in a Phase IIb Bangladesh cohort; deal closure is expected Q3 2024 and will expand Hilleman’s capacity to 50 million doses per annum via its new Dakar campus.

Regulators are simultaneously easing pathways: WHO’s September 2023 Emergency Use Listing (EUL) revision now accepts batch-release based on validated ELISA potency rather than animal challenge, trimming approval timelines by ~8 months and catalyzing interest from low-margin generics firms across India and Indonesia.

Consumer demand is shifting from reactive campaigns to preventive stockpiling; 12 African ministries pooled a USD 42 million advance purchase commitment through the Africa CDC, driving EuBiologics, Hilleman, and International Vaccine Institute to commit 25 million doses at a ceiling price of USD 1.20 per course—setting a new affordability benchmark for the category.

Analyst Overview

Cholera Vaccines Oral Live market outlook signals a highly attractive niche within the global travel & endemic disease space, underpinned by WHO pre-qualification tail-winds and rising post-pandemic immunization budgets. Competitive intensity is moderate: two WHO-approved strains dominate, yet emerging regional players in South Asia and Africa are poised to compress price bands by 15-20% within five years. The long-term trajectory is bullish—volume CAGR 11-12% through 2032, anchored by stockpiling for humanitarian emergencies and national introductions in GAVI-eligible countries, but pricing power erodes as volumes scale.

Innovation is shifting toward thermo-stable, single-dose presentations and bivalent variants offering ≥5-year protection, potentially reshaping demand curves beyond 2028. Near-term supply remains tight; global capacity utilization hovers at 85%, creating upside for technology-transfer partners. Key risks include regulatory delays in endemic-country approvals, cold-chain lapses during humanitarian deployments, and the possibility of cross-protection shortfalls against emergent non-O1 serogroups. Strategic investors should prioritize capacity expansion and late-stage pipeline assets to capture outsized share of the $450m peak sales opportunity forecast for 2032.

12 items

1. Executive Summary

2. Cholera Vaccines Oral Live Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Cholera Vaccines Oral Live Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Cholera Vaccines Oral Live Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Cholera Vaccines Oral Live Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.2. Global Cholera Vaccines Oral Live Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.3. Global Cholera Vaccines Oral Live Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Cholera Vaccines Oral Live Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Cholera Vaccines Oral Live Market Volume (K) and CAGR (%) by Type (2020-2032)

6.2.2. Global Cholera Vaccines Oral Live Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.3. Global Cholera Vaccines Oral Live Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Cholera Vaccines Oral Live Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Cholera Vaccines Oral Live Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Cholera Vaccines Oral Live Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Cholera Vaccines Oral Live Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Type

8.2.3. North America Volume (K) (2020-2032) by Application

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Type

8.3.3. South America Volume (K) (2020-2032) by Application

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Type

8.4.3. Europe Volume (K) (2020-2032) by Application

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Type

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Application

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Type

8.6.3. Asia Pacific Volume (K) (2020-2032) by Application

9. Global Cholera Vaccines Oral Live Market Competition by Key Manufacturers

9.1. Global Cholera Vaccines Oral Live Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Cholera Vaccines Oral Live: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. PaxVax

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Sanofi

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Valneva

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. EuBiologics

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Shanghai United Cell Biotechnology

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. Vabiotech

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Cholera Vaccines Oral Live Market

Figure 4: Global Cholera Vaccines Oral Live Market: Drivers

Figure 5: Global Cholera Vaccines Oral Live Market: Challenges

Figure 6: Global Cholera Vaccines Oral Live Market: Trends

Figure 7: Global Cholera Vaccines Oral Live Market: Opportunity

Figure 8: Global Cholera Vaccines Oral Live Market: Restraint

Figure 9: Global Cholera Vaccines Oral Live Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Type

Figure 15: Global Market Share (%) By Type (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Application

Figure 17: Global Market Share (%) By Application (2024)

Figure 18: Global Cholera Vaccines Oral Live Market Value (USD Million) By Region

Figure 19: Global Cholera Vaccines Oral Live Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Type

Figure 23: Global Market Share (%) By Type (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Application

Figure 25: Global Market Share (%) By Application (2032)

Figure 26: Global Cholera Vaccines Oral Live Market Value (USD Million) By Region

Figure 27: Global Cholera Vaccines Oral Live Market Share (%) By: Regions (2032)

Figure 28: Global Cholera Vaccines Oral Live Market Volume (K) By Region

Figure 29: Global Cholera Vaccines Oral Live Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Type

Figure 33: Global Market Share (%) By Type (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Application

Figure 35: Global Market Share (%) By Application (2032)

Figure 36: Global Cholera Vaccines Oral Live Market Value (USD Million) By Region

Figure 37: Global Cholera Vaccines Oral Live Market Share (%) By: Regions (2032)

Figure 38: Global Cholera Vaccines Oral Live Market Volume (K) By Region

Figure 39: Global Cholera Vaccines Oral Live Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

107 items

Table 1: Market Segmentation Analysis

Table 2: Global Cholera Vaccines Oral Live Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Cholera Vaccines Oral Live Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Cholera Vaccines Oral Live Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Market Volume (K) (2020-2024) By Type

Table 10: Global Market Share (%) By Type (2024)

Table 11: Global Market Volume (K) (2020-2024) By Application

Table 12: Global Market Share (%) By Application (2024)

Table 13: Global Cholera Vaccines Oral Live Market Value (USD Million) By Region

Table 14: Global Cholera Vaccines Oral Live Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Type

Table 17: North America Market Value (USD Million) (2020-2024) By Application

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Type

Table 20: Europe Market Value (USD Million) (2020-2024) By Application

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Type

Table 26: South America Market Value (USD Million) (2020-2024) By Application

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 30: Global Cholera Vaccines Oral Live Market Volume (K) By Region

Table 31: Global Cholera Vaccines Oral Live Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Type

Table 34: North America Market Volume (K) (2020-2024) By Application

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Type

Table 37: Europe Market Volume (K) (2020-2024) By Application

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Type

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Type

Table 43: South America Market Volume (K) (2020-2024) By Application

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Type

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 47: Global Cholera Vaccines Oral Live Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Cholera Vaccines Oral Live Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Cholera Vaccines Oral Live Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: PaxVax Basic Information And Sales Area

Table 52: PaxVax. Products Portfolio

Table 53: Sanofi Basic Information And Sales Area

Table 54: Sanofi. Products Portfolio

Table 55: Valneva Basic Information And Sales Area

Table 56: Valneva. Products Portfolio

Table 57: EuBiologics Basic Information And Sales Area

Table 58: EuBiologics. Products Portfolio

Table 59: Shanghai United Cell Biotechnology Basic Information And Sales Area

Table 60: Shanghai United Cell Biotechnology. Products Portfolio

Table 61: Vabiotech Basic Information And Sales Area

Table 62: Vabiotech. Products Portfolio

Table 63: Global Market Value (USD Million) (2025-2032) By Type

Table 64: Global Market Share (%) By Type (2032)

Table 65: Global Market Value (USD Million) (2025-2032) By Application

Table 66: Global Market Share (%) By Application (2032)

Table 67: Global Market Volume (K) (2025-2032) By Type

Table 68: Global Market Share (%) By Type (2032)

Table 69: Global Market Volume (K) (2025-2032) By Application

Table 70: Global Market Share (%) By Application (2032)

Table 71: Global Cholera Vaccines Oral Live Market Value (USD Million) By Region

Table 72: Global Cholera Vaccines Oral Live Market Share (%) By Region (2025-2032)

Table 73: North America Market Value (USD Million) (2025-2032) By Country

Table 74: North America Market Value (USD Million) (2025-2032) By Type

Table 75: North America Market Value (USD Million) (2025-2032) By Application

Table 76: Europe Market Value (USD Million) (2025-2032) By Country

Table 77: Europe Market Value (USD Million) (2025-2032) By Type

Table 78: Europe Market Value (USD Million) (2025-2032) By Application

Table 79: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 80: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 81: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 82: South America Market Value (USD Million) (2025-2032) By Country

Table 83: South America Market Value (USD Million) (2025-2032) By Type

Table 84: South America Market Value (USD Million) (2025-2032) By Application

Table 85: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 86: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 87: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 88: Global Cholera Vaccines Oral Live Market Volume (K) By Region

Table 89: Global Cholera Vaccines Oral Live Market Share (%) By Region (2025-2032)

Table 90: North America Market Volume (K) (2025-2032) By Country

Table 91: North America Market Volume (K) (2025-2032) By Type

Table 92: North America Market Volume (K) (2025-2032) By Application

Table 93: Europe Market Volume (K) (2025-2032) By Country

Table 94: Europe Market Volume (K) (2025-2032) By Type

Table 95: Europe Market Volume (K) (2025-2032) By Application

Table 96: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 97: Asia Pacific Market Volume (K) (2025-2032) By Type

Table 98: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 99: South America Market Volume (K) (2025-2032) By Country

Table 100: South America Market Volume (K) (2025-2032) By Type

Table 101: South America Market Volume (K) (2025-2032) By Application

Table 102: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 103: Middle East & Africa Market Volume (K) (2025-2032) By Type

Table 104: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 105: Research Programs/Design For This Report

Table 106: Key Data Information From Secondary Sources

Table 107: Key Data Information From Primary Sources

FAQs

1. What is the current Cholera Vaccines Oral Live market size?

The global Cholera Vaccines Oral Live market size surpassed USD 85 million in 2023, driven by rising travel vaccinations, WHO stockpiling, and endemic country immunization campaigns.

2. What growth rate is forecast for the next five years?

Analysts project an 11-13% CAGR through 2028, lifting the Cholera Vaccines Oral Live market valuation beyond USD 150 million as demand intensifies across Africa and South-East Asia.

3. Which factors are the key drivers of demand?

Key drivers include climate-driven outbreaks, increased traveller healthcare requirements, WHO pre-qualification programs, government stockpiling mandates, and affordable cold-chain-free formulations expanding reach in low-resource settings.

4. What challenges currently limit market expansion?

Supply shortages, single-donor dependence, complex regulatory pathways, limited commercial incentives for multinationals, and cold-chain gaps in cholera hotspots constrain rapid scale-up.

5. Which regions dominate consumption and production?

Africa and South-East Asia account for 80% of doses administered; India and South Korea host the bulk of WHO-pre-qualified Cholera Vaccines Oral Live production facilities.

6. Who are the leading companies in this space?

EuBiologics, Sanofi (past production), Shanghai United Cell, and International Vaccine Institute partners lead manufacturing; Serum Institute of India and Bharat Biotech are advancing second-generation bivalent oral live candidates.

7. What future opportunities offer the highest ROI?

Combination ETEC-cholera vaccines for travellers, thermostable presentations for last-mile delivery, and public-private stockpile contracts with Gavi and UNICEF present strong revenue potential.

8. How is technology reshaping vaccine development?

Synthetic biology accelerates strain engineering, single-use bioreactors cut capital costs, and lyophilization extends shelf life, collectively improving the future outlook for Cholera Vaccines Oral Live supply security.

9. How does the regulatory landscape influence market access?

WHO pre-qualification is mandatory for UN procurement; stringent lot-release testing, pharmacovigilance, and periodic WHO re-assessment add time and cost but ensure quality in the Cholera Vaccines Oral Live market.

10. Will pricing pressures affect profitability?

Tiered pricing for endemic countries and donor capitation keep per-dose margins modest; companies offset this via high-volume multi-year UNICEF tenders and premium traveller-clinic segments in developed markets.

Contact for Full Report

Loading report content...

Cholera Vaccines Oral Live Market Growth Drivers & Forecast 2033

Market Snapshot

Cholera Vaccines Oral Live Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Cholera Vaccines Oral Live Segmentation

Cholera Vaccines Oral Live Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Cholera Vaccines Oral Live market size?

2. What growth rate is forecast for the next five years?

3. Which factors are the key drivers of demand?

4. What challenges currently limit market expansion?

5. Which regions dominate consumption and production?

6. Who are the leading companies in this space?

7. What future opportunities offer the highest ROI?

8. How is technology reshaping vaccine development?

9. How does the regulatory landscape influence market access?

10. Will pricing pressures affect profitability?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Market Snapshot

Cholera Vaccines Oral Live Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Cholera Vaccines Oral Live Segmentation

Cholera Vaccines Oral Live Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Cholera Vaccines Oral Live market size?

2. What growth rate is forecast for the next five years?

3. Which factors are the key drivers of demand?

4. What challenges currently limit market expansion?

5. Which regions dominate consumption and production?

6. Who are the leading companies in this space?

7. What future opportunities offer the highest ROI?

8. How is technology reshaping vaccine development?

9. How does the regulatory landscape influence market access?

10. Will pricing pressures affect profitability?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation